James Healy

James Healy

Director/Board Member at ARRIVENT BIOPHARMA, INC.

Net worth: 110 M $ as of 31/08/2026

61 year
Health Technology
Finance
Commercial Services

Profile

Currently, James Irvin Healy is Director at Sorbent Therapeutics, Inc., Iterum Therapeutics International Ltd., Iterum Therapeutics US Holding Ltd., and Atsena Therapeutics, Inc. He serves as Independent Director at Arrivent BioPharma, Inc. (since 2023), Rapport Therapeutics, Inc. (since 2023), BioAge Labs, Inc. (since 2024), and Seaport Therapeutics, Inc. (since 2024).
He is General Partner at Sofinnova Venture Partners VII LP and Managing Partner at Sofinnova Investments, Inc. (since 2000), Sofinnova Management VI LLC, Sofinnova Management VII LLC (since 2012), and Sofinnova Investments, Inc. (Investment Management) (since 2000).
Formerly, he was Chairman at Hyperion Therapeutics, Inc. (2012–2015) and Y-mAbs Therapeutics, Inc. (2022–2025).
He was Vice Chairman at Auris Medical AG and Auris Medical Holding AG.
He served as Independent Non-Executive Director at Amarin Corp.
Plc (2012–2016), Independent Director at InterMune, Inc. (2011–2014), Anthera Pharmaceuticals, Inc. (2011–2014), Edge Therapeutics, Inc. (2015–2018), Ascendis Pharma A (2014–2022), NuCana Plc (2014–2022), Coherus Oncology, Inc. (2014–2022), Iterum Therapeutics Plc (2015–2020), and Natera, Inc. (2014–2025).
He was Director at CoTherix, Inc. (2001–2007), Novacea, Inc. (2001–2009), Movetis NV (2007–2010), PregLem SA (2009–2010), ObsEva SA (2013–2021), CinCor Pharma, Inc. (2019–2023), and others.
He was Lead Independent Director at Bolt Biotherapeutics, Inc. (2021–2024) and Independent Director at Karuna Therapeutics, Inc. (2019–2024).
Earlier roles include Manager at ISTA Pharmaceuticals, Inc. (1997–1998) and Associate at Sanderling Management CO LLC (1996).
Education includes undergraduate degree from the University of California, Berkeley (1990) and doctorate from Stanford University School of Medicine and Stanford University (1998).

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
10/06/2026 1,947,579 ( 4.06% ) 95 M $ 31/08/2026
25/04/2025 46,260 ( 0.03% ) 15 M $ 31/08/2026
10/06/2026 0 ( -.--% ) - $ 31/08/2026

James Healy active positions

CompaniesPositionStart
ARRIVENT BIOPHARMA, INC. Director/Board Member 01/03/2023
RAPPORT THERAPEUTICS, INC. Director/Board Member 23/08/2023
BIOAGE LABS, INC. Director/Board Member 01/02/2024
Private Equity Investor 01/06/2000
Corporate Officer/Principal -
Director/Board Member -
Director/Board Member -
Chief Executive Officer 01/06/2000
Director/Board Member -
░░░░░░░░░ ░░░░░░░░░░ ░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ -

Former positions of James Healy

CompaniesPositionEnd
░░░░ ░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░░░░░
See the detail of James Healy's experience

Training of James Healy

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

65

1st degree connections

54

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies54

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Bayer Pharmaceuticals Corp.

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Finance

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Sofinnova Management VI LLC

Sofinnova Management VII LLC

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Finance

Health Technology